At present, Artepharm Co. is one of the technology leaders in the anti-malarial drug market, and they are striving to get their products into the private and public anti-malarial drug market channels around the world. Artepharm Global Corp. iscommitted to promoting their FEMSE program in hyperendemic malaria countries worldwide, promoting the distribution of Artequick and thereby gaining substantial market share.
At the product level, Artepharm Co. is competing directly with Novartis (Switzerland), Sanofi (France), the Holley Group (China) and other anti-malarial drugs manufacturers. Compared to similar products and technologies, their anti-malarial drug and malaria control technology is based on the technical aspects of malaria control. Artepharm Co.’s FEMSE technology has competitiveness because of the limited effectiveness of current global mainstream anti-malarial methods. Artepharm Co.’s effectiveness and cost-savings provide a significant breakthrough for the implementation of global eradication of malaria.